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6.1
A SENSITIVE AND REPRODUCIBLE METHOD FOR 
IDENTIFICATION OF RADIATION-INDUCED MUTATIONS: 
IMPLICATIONS FOR RADIATION TREATMENT 
&AN&PROTECTION
M Boyd , K Hughes , A Livingstone , AM Clark , N Baig , L Wilson ,
S Ross , K Prise , RJ Mairs 
1 United Kingdom, CRUK Beatson Labs, Glasgow, 2 United Kingdom, 
Department of Clinical Physics, Glasgow, 3 United Kingdom,
Gray Laboratories, London
Characterisation of the mutations induced by ionising radiation is required to 
improve radiation protection, to identify radiotherapy patients whose normal 
tissues are abnormally prone to radiation damage and to optimise radiotherapy 
and limit radiation-induced second tumours. Hypervariable tandemly repeated 
nucleotide sequences (mini- and microsatellites) have been shown to be 
mutable by radiation and several studies have indicated an increase in the 
minisatellite mutation rate in human and murine germ cells post irradiation.
Utilising these sequences, we have developed a sensitive and reproducible 
methodology, Automated Fluorescent Fragment Analysis, for analysis of 
radiation mutagenesis in somatic cells.  We identiﬁ  ed a radiation dose-
response relationship for mutation induction in UVW human glioma cells 
and observed that, with respect to detection of genetic aberrations, the 
analysis of hypervariable repeat sequences was 100 to 1000 fold more 
sensitive than conventional methodology utilising coding loci.  We detected 
a 4-fold higher mutation rate in hypervariable loci after treatment of cells 
with 0.3 Gy rather than 3 Gy gamma radiation.  This ﬁ  nding has implications 
for the initiation of radiation-mediated second tumours as a result of the low 
dose exposure of normal tissues during radiotherapy. 
In order to assess the environmental implications of EMF population 
exposure, we are currently using our novel methodology for the analysis 
of mutations induced by EMF radiation.  We are also applying this 
sensitive assay to mutation detection in individuals who are heterozygous 
for the Ataxia Telangiectasia (AT) gene in order to determine whether low 
penetrance genes may render such individuals susceptible to radiation 
mediated cancers.  These studies may lead to modiﬁ  cation of radiotherapy 
treatment planning and identify subsets of the population unsuitable for 
radiation-based medical screening procedures involving X-rays.
6.2
THE MOLECULAR PATHOLOGY OF POST-CHERNOBYL 
THYROID CANCER: IS THERE A RADIATION SIGNATURE?
GA Thomas 
South West Wales Cancer Institute, University of Wales on behalf of 
CHIPS EC consortium, Swansea, United Kingdom
The incidence of papillary thyroid cancer (PTC) in those areas exposed
to fallout from the Chernobyl accident has increased dramatically,
particularly in those under 19 at exposure.  To determine whether there is a
radiation signature, we studied the molecular pathology of post Chernobyl
thyroid cancer using a variety of techniques on material supplied by the
Chernobyl Tissue Bank (www.chernobyltissuebank.com).
Ret rearrangement was studied by RT-PCR in 100 papillary cancers from 
patients aged under 15 at the time of the Chernobyl accident; 44% of these 
harboured ret rearrangements; the frequency in PTCs from children in England 
and Wales is 48%. There was no correlation with either age at exposure or 
latency. We also studied 43 of these tumours using FISH for ret.  We found 
that the majority of PTCs harboured positive cells with the translocation, and 
the maximum number of positive nuclei was 55%.    There was a discrepancy 
between cases positive by RT-PCR (41%) and FISH (72%).  Further 
investigation showed that 31% of cases showed clustering of positive nuclei, 
suggesting subclonal growth.  Sampling of different areas of the tumour is 
likely to account for differences between FISH and RT-PCR results.
Expression analysis of 2400 genes was also performed 12 cases of
PTC using Micromax cDNA array and compared  with 9 PTCs from
Belgium and France.  Hierarchical clustering analysis on the 50% most
expressed genes showed no differences between the 2 groups of tumours.
Permutation analyses revealed differences in the expression of 10 genes;
5 of these related to lymphoid inﬁ  ltration in the tumours, the other 5
showed small differences in expression, and are therefore likely to be of
no biological signiﬁ  cance.  These results suggest there is no molecular
signature for radiation induced thyroid cancer.  The molecular biological
features of post Chernobyl PTCs may relate more to the age of the patients
studied, rather than their aetiology.
6.3
THE INDUCTION OF TUMOUR HYPOXIA BY VASCULAR 
DISRUPTING AGENTS AND THE IMPLICATIONS FOR 
COMBINATION WITH RADIATION THERAPY
M.R. Horsman , R. Murata 
Dept. Experimental Clinical Oncology, Aarhus University Hospital, 
Aarhus, Denmark
Introduction: Combining vascular disrupting agents (VDAs) with 
conventional treatments is a novel approach for cancer therapy. But, the 
VDA-induced reductions in tumour blood ﬂ   ow could increase hypoxia 
that may impact the other therapy. This study investigated the induction of 
hypoxia by VDAs and what affect that had on radiation response. 
Methods: A C3H mammary carcinoma grown in the right rear foot of 
female CDF1 mice was used when at 200 mm3. The VDAs, injected i.p., were 
combretastatin A-4 disodium phosphate (CA4DP; 250 mg/kg), ZD6126 (200 
mg/kg) and 5,6-dimethylxanthenone-4-acetic acid (DMXAA, 20 mg/kg). 
Tumour oxygenation (pO2) was estimated using the Eppendorf histograph. 
Single dose radiation (240 kV x-rays) was given locally to the tumour and 
response assessed using either growth delay (time for tumours to reach 3x 
treatment volume) or tumour control (percent of animals showing tumour 
control at 90 days).
Results: The mean (+ 1 SE) percent pO2 values < 5 mmHg measured in 
control tumours was 45 + 5. At 1-hour after giving CA4DP or ZD6126 or 3-
hours after DMXAA (times of maximum blood ﬂ  ow reductions) these were 
signiﬁ  cantly (Student’s t-test; p<0.05) increased to 91 + 4, 73 + 7 and 87 + 
9, respectively. Irradiating tumours and then injecting VDAs within 1-hour 
enhanced radiation response by factors of 1.2 (CA4DP), 1.1 (ZD6126) and 
1.3 (DMXAA). Giving the radiation 1-hour after CA4DP or 3-hours after 
DMXAA resulted in a protective response, the enhancements being 0.96 and 
0.74, respectively.    
Conclusions: VDAs increased tumour hypoxia and irradiating at the time 
of this hypoxia induction reduced radiation response. Such an effect could 
impact the combination of VDAs and radiation when given in a clinically 
relevant fractionated schedule. Additional studies are now being performed 
to determine the time-dependency for the disappearance of this hypoxic 
resistance.  
Supported by a grant from the Danish Cancer Society
6.4
CYTOKINE MODULATION OF INOS EXPRESSION IN HUMAN 
TUMOUR CELLS ENHANCES RADIATION RESPONSE AND 
ACTIVATION OF BIOREDUCTIVE DRUGS
S Singh , EC Chinje , IJ Stratford 
Ireland, The University of Manchester, Manchester
Hypoxia regulates the expression of cytokine-inducible nitric oxide synthase
(iNOS) gene which catalyses the conversion of L-arginine to L-citrulline
and nitric oxide (NO) in the presence of O2 as a co-factor. iNOS can activate
hypoxia selective bioreductive drugs and NO can sensitise hypoxic cells
to radiation. Thus, in this study we determined the contribution of tumour
iNOS to radiation and bioreductive drug sensitivity in air, hypoxia and at
intermediate O2 tensions.
Human breast tumour cells (MDA231) were exposed to cytokine-mix (CM)
{IFN-γ (100ng/ml) + LPS (50µg/ml)} for 24h in air, anoxia or different O2
tensions (0.02%-2%). CM was then washed out from cultures and cells re-
incubated for further 24h in the different O2 tensions, at which time cells were
either exposed to the drugs (RSU1069 or TPZ) for 3h or irradiated at 370C
and cell survival assessed by clonogenic assay. At the time of drug exposure,
samples of cells were harvested and NADPH-dependent iNOS-reductase
activity (NOSR), total iNOS activity (citrulline assay) and NO production
(Griess assay) were determined.
NO output reached maximum levels 24hr after cytokine exposure at 2%
O2 (36µM compared to 1.62µM for untreated cells). This increased NO
production had no impact on radiosensitivity of aerobic cells, but at lower
O2 range (≤1%O2), a positive correlation between NO release and increase in
radiation response was found. For example, at 1% O2, where in uninduced cells
the OER was 1.13; when cells were treated with CM the OER increased to
1.84. This increase in OER was abolished when the iNOS inhibitor L-NMMA
was present during induction and irradiation of the cells. CM resulted in
2.16-fold increase in NOSR activity (7.23 compared to 3.34 nmol/mg protein
for untreated cells).  Cytotoxicity ratios for air/anoxia were 3.5 (untreated)
and 8.25(CM) for TPZ, and 1.94 (untreated) and 3.43 (CM) for RSU1069,
respectively. For air/0.5%O2 ratios were 2.6 (untreated) and 6.0 (CM) for TPZ,
and 1.26 (untreated) and 1.71(CM) for RSU1069, respectively.
This study shows that, at intermediate O2, characteristic of hypoxic solid
tumours, iNOS enzyme can catalyse activation of hypoxic cytotoxins TPZ
and RSU1069. We also demonstrate that, NO produced endogenously can
contribute to overall tumour radiosensitivity.
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EXPERIMENTAL PRECLINICAL THERAPY, USING [131I]MIBG, 
OF TUMOURS TRANSFECTED WITH THE NORADRENALINE 
TRANSPORTER GENE
M Boyd , SC Ross , J Owens , RJ Mairs 
CRUK Beatson Laboratories, Glasgow, UK
Radiolabelled meta-iodobenzylguanidine (MIBG), an analogue of 
neuroadrenergic blockers, is used for imaging and treatment of neural 
crest-derived tumors, such as neuroblastoma and phaeochromocytoma, 
which express the targeted noradrenaline transporter (NAT).  To 
determine whether [131I]MIBG could also treat other tumor types, we 
transfected UVW human glioma cells with the NAT gene.  These were 
used for the evaluation of radiopharmaceutical uptake in vitro and for the 
establishment of nude mouse xenografts.  
By virtue of NAT gene transfer, the accumulation of [131I]MIBG was 
enhanced 25-fold in UVW cells. The distribution of MIBG in tumour-
bearing nude mice was compared by measurement of radioactivity in 
tissues excised from the animals. Twenty four  hours after administration 
of [131I]MIBG tumours not expressing the NAT took up only low levels 
of activity whereas the concentration of radiopharmaceutical in NAT 
bearing experimental tumours was 3.17 percent of injected dose per 
gram of tissue. In contrast, the concentration of MIBG was low in liver, 
kidney, lung thyroid and marrow. 
I.p. injection of [131I]MIBG signiﬁ  cantly suppressed the growth of UVW/
NAT tumours in a dose-dependent manner .Control tumours reached a 
ten-fold increase in volume in 17.2 ± 2.1 days, whereas the volume of 
tumours treated with the 14 MBq of [131I]MIBG produced a cure rate of 
100%. There was no evidence of thrombocytopenia and no signiﬁ  cant 
difference in platelet count observed thirty days after treatment with a 
[131I]MIBG .  Likewise, the clonogenic capacity of pluripotential stem 
cells was not adversely effected by [131I]MIBG treatment.
These results suggest that tumour-speciﬁ  c transfection of the NAT gene 
is a promising therapeutic strategy with minimal dose limiting organ 
toxicity.
6.6
ENHANCEMENT OF TARGETED RADIOTEHRAPY IN 
NEUROBLASTOMA: A NOVEL GENE THERAPY APPROACH
M Boyd , E Cosimo , AG McCluskey , AM Clark , T Robson ,
HO McCarthy , MR Zalutsky , RJ Maits 
1 CRUK Beatson Labs, Glasgow, United Kingdom, 2 Dept Radiology, 
Duke University, Durham, United States, 3 Centre for Biomolecular 
Sciences, Ulster University, coleraine, United Kingdom
Neuroblastoma, is one of the most common solid tumours in children.
As the cure rate of neuroblastoma is low, new therapeutic approaches are
necessary. The radiopharmaceutical [131I]MIBG has produced encouraging
results (long term remissions and palliation) in neuroblastoma patients and
increased effectiveness could be obtained by increased concentration of the
[131I]MIBG in malignant cells.  We previously reported that transfection
of the NAT gene into neuroblastoma cells, induced the expression of a
functional transporter which improved the active uptake of [131I]MIBG and
resulted in dose-dependent toxicity to the host cells.
A construct with radiation-inducible WAF1 promoter driving NAT should
be able to upregulate the synthesis of the NAT in neuroblastoma cells.
This strategy involves WAF1/NAT transfection followed by an initial
dose of radiation in the form of [131I]MIBG (concentrated preferentially
by neuroblastoma cells), facilitating the tumour-speciﬁ  c overexpression of
NAT. A second administration of [131I]MIBG should be avidly concentrated
by target tumour cells, leading to their sterilisation.
We transfected a neuroblastoma cell line (SK-N-BE) with a plasmid
containing the GFP cDNA controlled by the radiation-inducible promoter
of WAF1. According to FACS analysis, a 4 Gy dose of gamma radiation
increased the GFP protein level to 11.7 times the unirradiated cells protein
level.  Using the same conditions, preliminary studies showed that low
doses of targeted radionuclides of different radiation quality (α−, β− and
Auger emitters), [123I]MIBG (0.5MBq/ml), [131I]MIBG (0.5MBq/ml) and
[211At]MABG(50 nCi/ml)  increased GFP protein level to at least 3.5 times
the unirradiated cells protein level. These encouraging results suggest that
the promoter of WAF1 is a promising means of driving the over-expression
of the NAT gene in neuroblastoma cells in a radiation-dependent manner. 
6.7
RADIATION-INDUCED BYSTANDER SIGNALLING IN 
TARGETED GLIOMA CELLS
C Shao , VC Stewart , M Folkard , BD Michael , KM Prise 
Gray Cancer Institute, Northwood, United Kingdom
Bystander responses have been reported to be a major determinant 
of the response of cells to radiation exposure at low doses, including 
those of relevance to therapy. Human glioblastoma T98G cell nuclei 
were individually irradiated with an exact number of helium ions 
using a single-cell microbeam. It was found that when only one cell in 
a population of ~1200 cells was targeted, with one or ﬁ  ve ions, cellular 
damage measured as induced micronuclei was increased by 20%. The 
level of bystander response was independent of whether radiation was 
targeted through the nucleus or cytoplasm only. However when c-PTIO, 
a nitric oxide-speciﬁ  c scavenger was present in the culture medium, the 
micronuclei yields reduced to the predicted values. By using DAF-FM, 
NO was detected in situ, and it was found that NO-induced ﬂ  uorescence 
intensity in the irradiated population where 1% of cell nuclei were 
individually targeted with a single helium ion was increased relative to 
control with around 40% of the cells showing increased NO levels.  
We have also detected bystander interactions between T98G glioma 
cells and normal primary human ﬁ  broblasts (AG01522), co-cultured 
within the same dish. A fraction of cells within one population was 
individually targeted through the nucleus with exactly one or ﬁ  ve 
helium particles (3He2+) and micronuclei formation in the bystander 
nonirradiated population was measured. When only 1% of cell nuclei 
were irradiated, the NO level in the T98G population was increased by 
31% and the ROS level in the AG0 population was increased by 18%. 
Treatment of cultures with c-PTIO abolished the bystander micronuclei 
induction in nonirradiated AG01522 cells but only partly attenuated 
the bystander response in nonirradiated T98G cells and this could be 
eliminated by treatment with DMSO. This suggests that differential 
mechanisms involving NO or ROS mediated signaling, dependent on 
the cell type targeted, were involved.
6.8
RADIOTHERAPY FRACTIONATION: RESULTS OF A PILOT 
STUDY TO THE NCRI STANDARDISATION OF RADIOTHERAPY 
(START) TRIAL
J Yarnold 1, A Ashton 2, J Bliss 3, B Broad 2, J Homewood 3,
C Jackson 3, J Regan 1, J Haviland 3, S Bentzen 4, JR Owen 2
1 United Kingdom, Royal Marsden Hospital, Sutton, 2 United 
Kingdom, Cheltenham Oncology Centre, Cheltenham, 3 United 
Kingdom, Institute of Cancer Research, Sutton, 4 United Kingdom, 
Gray Cancer Institute, Northwood
Aim: To test the effects of fraction size > 2.0Gy on i) late normal tissue response 
and ii) tumour control in the breast after tumour excision and radiotherapy for 
early breast cancer.
Methods: 1410 women with T1-3 N0-1 M0 invasive breast cancer were 
randomised between 1986-98 into one of three radiotherapy regimens after 
local excision of early stage breast cancer; 50Gy in 25 fractions (F) vs two dose 
levels of a test schedule giving 39.0Gy or 42.9Gy in 13F over 5 weeks. Fractions 
sizes were 2.0Gy, 3.0Gy and 3.3Gy respectively. The primary endpoint was late 
change in breast appearance compared to post-surgical appearance scored from 
annual photographs scored blind to treatment allocation. Secondary endpoints 
included palpable breast induration and ipsilateral tumour recurrence.
Results: With a minimum follow up of 5 years, the risk of scoring any change in 
breast appearance after 50Gy/25F, 39Gy/13F and 42.9Gy/13F was 35.4% 27.4% 
and 42.3% respectively, from which an a ⁄β value of 3.6Gy (95% CI 1.8 - 5.4) 
can be derived. The α⁄β value for palpable breast induration was 3.1Gy (95% 
CI 1.8 - 4.4). Local tumour control at 10 years was 87.0%, 85.6% and 88.6% 
respectively, from which a ⁄β value of 4.1Gy (95% CI 1.0 – 9.7) can be derived.
Discussion:  The estimated α⁄β value for tumour control is imprecise, but 
appears lower than that for squamous carcinomas and comparable to those of 
late reacting normal tissues. If the UK START trial conﬁ  rms these ﬁ  ndings, there 
will be a strong case for testing a regimen of whole breast radiotherapy based on 
5 fractions of intensity modulated radiotherapy (proposed UK FAST trial)
Conclusion: the data are consistent with the hypothesis that fraction sizes > 
2.0Gy are safe and effective when irradiating the breast. They strengthens the 
case for adjusting dose intensity by modulating fraction size rather than fraction 
number, an approach proposed for evaluation in the UK IMPORT trial.
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